UNSPSC 51271910: Leucinocaine

This classification denotes an anesthetic agent with the molecular formula C17H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64DXV166PH, chemically known as 1-pentanol, 2-(diethylamino)-4-methyl-, p-aminobenzoate (ester) but generally known as leucinocaine, which bears US NIH Compound Identifier 68648. European Medicines Agency schedules Leucinocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08447MIG.

UNSPSC 51271910 Leucinocaine, a Commodity code, addresses generic and brand-name local anesthetic pharmaceuticals procured through cooperative purchasing agreements and direct state and local health agency contracts. State and local governments buy leucinocaine and similar injectable anesthetics for hospital surgical suites, outpatient procedural centers, dental clinics, and emergency departments. The issuing bodies under this code are primarily state health departments and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions; individual counties and municipal health systems also solicit independently. Procurement typically occurs through RFPs that establish master agreements with pharmaceutical manufacturers or authorized distributors, with pricing negotiated at the contract level and individual purchase orders issued against standing agreements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. The solicitation requires vendors to certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and demonstrate pricing flexibility through flat-price, net-price formats, or WAC-minus structures. Awarded vendors will be available to wholesalers by May 15, 2026, with contract effectiveness on July 1, 2026, and a two-year initial term with optional extensions. Evaluation weighting emphasizes price competitiveness (75 percent), with the remaining 25 percent split among fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee.